Joshua Keefe1, Chen Yao1, Shih-Jen Hwang1, Paul Courchesne1, Gha Young Lee1, Josée Dupuis2, Joseph P Mizgerd3, George O'Connor3, George R Washko4, Michael H Cho5, Edwin K Silverman5, Daniel Levy6. 1. Framingham Heart Study, Framingham, MA; Population Sciences Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD. 2. Department of Biostatistics, Boston University School of Public Health, Boston, MA. 3. Pulmonary Center and Department of Medicine, Boston University School of Medicine, Boston, MA. 4. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA. 5. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA; Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA. 6. Framingham Heart Study, Framingham, MA; Population Sciences Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD. Electronic address: levyd@nih.gov.
Abstract
BACKGROUND: There are few clinically useful circulating biomarkers of lung function and lung disease. We hypothesized that genome-wide association studies (GWAS) of circulating proteins in conjunction with GWAS of pulmonary traits represents a clinically relevant approach to identifying causal proteins and therapeutically useful insights into mechanisms related to lung function and disease. STUDY QUESTION: Can an integrative genomic strategy using GWAS of plasma soluble receptor for advanced glycation end-products (sRAGE) levels in conjunction with GWAS of lung function traits identify putatively causal relations of sRAGE to lung function? STUDY DESIGN AND METHODS: Plasma sRAGE levels were measured in 6,861 Framingham Heart Study participants and GWAS of sRAGE was conducted to identify protein quantitative trait loci (pQTL), including cis-pQTL variants at the sRAGE protein-coding gene locus (AGER). We integrated sRAGE pQTL variants with variants from GWAS of lung traits. Colocalization of sRAGE pQTL variants with lung trait GWAS variants was conducted, and Mendelian randomization was performed using sRAGE cis-pQTL variants to infer causality of sRAGE for pulmonary traits. Cross-sectional and longitudinal protein-trait association analyses were conducted for sRAGE in relation to lung traits. RESULTS: Colocalization identified shared genetic signals for sRAGE with lung traits. Mendelian randomization analyses suggested protective causal relations of sRAGE to several pulmonary traits. Protein-trait association analyses demonstrated higher sRAGE levels to be cross-sectionally and longitudinally associated with preserved lung function. INTERPRETATION: sRAGE is produced by type I alveolar cells, and it acts as a decoy receptor to block the inflammatory cascade. Our integrative genomics approach provides evidence for sRAGE as a causal and protective biomarker of lung function, and the pattern of associations is suggestive of a protective role of sRAGE against restrictive lung physiology. We speculate that targeting the AGER/sRAGE axis may be therapeutically beneficial for the treatment and prevention of inflammation-related lung disease. Published by Elsevier Inc.
BACKGROUND: There are few clinically useful circulating biomarkers of lung function and lung disease. We hypothesized that genome-wide association studies (GWAS) of circulating proteins in conjunction with GWAS of pulmonary traits represents a clinically relevant approach to identifying causal proteins and therapeutically useful insights into mechanisms related to lung function and disease. STUDY QUESTION: Can an integrative genomic strategy using GWAS of plasma soluble receptor for advanced glycation end-products (sRAGE) levels in conjunction with GWAS of lung function traits identify putatively causal relations of sRAGE to lung function? STUDY DESIGN AND METHODS: Plasma sRAGE levels were measured in 6,861 Framingham Heart Study participants and GWAS of sRAGE was conducted to identify protein quantitative trait loci (pQTL), including cis-pQTL variants at the sRAGE protein-coding gene locus (AGER). We integrated sRAGE pQTL variants with variants from GWAS of lung traits. Colocalization of sRAGE pQTL variants with lung trait GWAS variants was conducted, and Mendelian randomization was performed using sRAGE cis-pQTL variants to infer causality of sRAGE for pulmonary traits. Cross-sectional and longitudinal protein-trait association analyses were conducted for sRAGE in relation to lung traits. RESULTS: Colocalization identified shared genetic signals for sRAGE with lung traits. Mendelian randomization analyses suggested protective causal relations of sRAGE to several pulmonary traits. Protein-trait association analyses demonstrated higher sRAGE levels to be cross-sectionally and longitudinally associated with preserved lung function. INTERPRETATION: sRAGE is produced by type I alveolar cells, and it acts as a decoy receptor to block the inflammatory cascade. Our integrative genomics approach provides evidence for sRAGE as a causal and protective biomarker of lung function, and the pattern of associations is suggestive of a protective role of sRAGE against restrictive lung physiology. We speculate that targeting the AGER/sRAGE axis may be therapeutically beneficial for the treatment and prevention of inflammation-related lung disease. Published by Elsevier Inc.
Authors: Nefertiti C dupont; Kehui Wang; Pathik D Wadhwa; Jennifer F Culhane; Edward L Nelson Journal: J Reprod Immunol Date: 2005-08 Impact factor: 4.054
Authors: Michael H Cho; Peter J Castaldi; Craig P Hersh; Brian D Hobbs; R Graham Barr; Ruth Tal-Singer; Per Bakke; Amund Gulsvik; Raúl San José Estépar; Edwin J R Van Beek; Harvey O Coxson; David A Lynch; George R Washko; Nan M Laird; James D Crapo; Terri H Beaty; Edwin K Silverman Journal: Am J Respir Crit Care Med Date: 2015-09-01 Impact factor: 21.405
Authors: Wei Sun; Katerina Kechris; Sean Jacobson; M Bradley Drummond; Gregory A Hawkins; Jenny Yang; Ting-Huei Chen; Pedro Miguel Quibrera; Wayne Anderson; R Graham Barr; Patricia V Basta; Eugene R Bleecker; Terri Beaty; Richard Casaburi; Peter Castaldi; Michael H Cho; Alejandro Comellas; James D Crapo; Gerard Criner; Dawn Demeo; Stephanie A Christenson; David J Couper; Jeffrey L Curtis; Claire M Doerschuk; Christine M Freeman; Natalia A Gouskova; MeiLan K Han; Nicola A Hanania; Nadia N Hansel; Craig P Hersh; Eric A Hoffman; Robert J Kaner; Richard E Kanner; Eric C Kleerup; Sharon Lutz; Fernando J Martinez; Deborah A Meyers; Stephen P Peters; Elizabeth A Regan; Stephen I Rennard; Mary Beth Scholand; Edwin K Silverman; Prescott G Woodruff; Wanda K O'Neal; Russell P Bowler Journal: PLoS Genet Date: 2016-08-17 Impact factor: 5.917
Authors: Karsten Suhre; Matthias Arnold; Aditya Mukund Bhagwat; Richard J Cotton; Rudolf Engelke; Johannes Raffler; Hina Sarwath; Gaurav Thareja; Annika Wahl; Robert Kirk DeLisle; Larry Gold; Marija Pezer; Gordan Lauc; Mohammed A El-Din Selim; Dennis O Mook-Kanamori; Eman K Al-Dous; Yasmin A Mohamoud; Joel Malek; Konstantin Strauch; Harald Grallert; Annette Peters; Gabi Kastenmüller; Christian Gieger; Johannes Graumann Journal: Nat Commun Date: 2017-02-27 Impact factor: 14.919
Authors: Chen Yao; George Chen; Ci Song; Joshua Keefe; Michael Mendelson; Tianxiao Huan; Benjamin B Sun; Annika Laser; Joseph C Maranville; Hongsheng Wu; Jennifer E Ho; Paul Courchesne; Asya Lyass; Martin G Larson; Christian Gieger; Johannes Graumann; Andrew D Johnson; John Danesh; Heiko Runz; Shih-Jen Hwang; Chunyu Liu; Adam S Butterworth; Karsten Suhre; Daniel Levy Journal: Nat Commun Date: 2018-08-15 Impact factor: 14.919
Authors: Claudia Giambartolomei; Damjan Vukcevic; Eric E Schadt; Lude Franke; Aroon D Hingorani; Chris Wallace; Vincent Plagnol Journal: PLoS Genet Date: 2014-05-15 Impact factor: 5.917
Authors: Jenna N McNeill; Dong Heon Lee; Shih-Jen Hwang; Paul Courchesne; Chen Yao; Tianxiao Huan; Roby Joehanes; George T O'Connor; Jennifer E Ho; Daniel Levy Journal: PLoS One Date: 2022-04-07 Impact factor: 3.240